Glycogen synthase kinase-3 as drug target: from wallflower to center of attention.
Some 20 years ago, glycogen synthase kinase-3 (GSK-3) was categorized as one of several protein kinases that could phosphorylate glycogen synthase and regulate the glucose metabolism pathway. Today, GSK-3 is being identified as a ubiquitous serine/threonine protein kinase that participates in a multitude of cellular processes, ranging from cell membrane-to-nucleus signaling, gene transcription, translation, cytoskeletal organization to cell cycle progression and survival. Two functional aspects make GSK-3 a peculiar kinase: its activity is constitutive and downregulated after cell activation by phosphorylation or interaction with inhibitory proteins, and the enzyme prefers substrates that are specifically prepared, that is prephosphorylated, by other kinases. Its pleiotropic but unique activities have made GSK-3 a much sought-after target for the treatment of prevalent human diseases such as type 2 diabetes and Alzheimer's disease. Recent drug discovery efforts have identified small-molecule, orally active inhibitors of GSK-3. This accomplishment may represent the first step toward the development of novel therapeutic agents.
Van Wauwe
Jean
J
Department of Inflammation, Johnson & Johnson Pharmaceutical R&D, a Division of Janssen Pharmaceutica, Beerse, Belgium. jvwauwe@prdbe.jnj.com
Haefner
Burkhard
B
D000544:Alzheimer Disease / Q000188:drug therapy / Q000201:enzymology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000201:enzymology; D016503:Drug Delivery Systems / Q000379:methods*; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000201:enzymology; D010766:Phosphorylation
D004791:Enzyme Inhibitors; D038362:Glycogen Synthase Kinase 3